Joshua Bleharski, Ph.D., is the Chief Financial Officer at IDEAYA Biosciences Inc., a clinical-stage precision oncology company focused on developing targeted therapies for cancer patients. With over 25 years of experience in the biotechnology and pharmaceutical sectors, Dr. Bleharski brings deep expertise in financial strategy, capital raising, mergers and acquisitions, and operational leadership. He holds a Ph.D. in Pharmacology from the University of California, San Francisco, and an MBA from Columbia Business School. Prior to joining IDEAYA in 2021, Dr. Bleharski served as CFO of Aduro Biotech, Inc., where he guided the company through a pivotal merger with Chinook Therapeutics and multiple financing initiatives. His earlier career includes key finance and operations roles at Nektar Therapeutics, Genentech, and biotech investment firms, during which he orchestrated over $1 billion in capital raises and strategic partnerships that advanced innovative drug pipelines. At IDEAYA, Dr. Bleharski oversees all financial operations, investor relations, corporate development, and treasury functions, playing a critical role in supporting the company's expansion of its synthetic lethality-based oncology portfolio and achieving key clinical milestones.